Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma

Becker, Gerd; Jeremić, Branislav; Pitz, Susanne; Buchgeister, Markus; Wilhelm, Helmut; Schiefer, Ulrich; Paulsen, Frank; Zrenner, Eberhart; Bamberg, M.

doi:10.1016/s0360-3016(02)03753-7

Cited by 109 publications

(63 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other side effects were dry eye, orbital pain (in a patient suffering form migraine), and iritis, which responded well to local steroid therapy. In contrast, the other studies dealing with pONSM providing clearly documented treatment parameters [57][58][59] showed excellent treatment outcome (improved or stable vision in 100% of patients in both studies) and no toxicity to optic pathways were observed. The follow-up in these studies ranged from 1-7 years (mean, 3 years; median, 2 years), 58 and 1-6 years (median, 35.5 months).…”

Section: Treatmentmentioning

confidence: 69%

“…33,43,57,59,74,78,85 However, only recently has excellent functional outcome matched with very low toxicity been enabled by modern RT techniques. This holds even truer as RT candidates represent an unfavorable group of patients suffering from ''clinically active'' disease, characterized by progressive vision impairment.…”

Section: Discussionmentioning

confidence: 99%

“…The characteristics of these studies and the outcome are given in Table 1, including the most recent multi-institutional study by Baumert et al, 78 and smaller studies of Richards et al, 79 Landert et al, 80 a report of a case by Paridaens et al, 81 and the most recent report by Sitathanee et al, 82 all published later on. Liu et al, 58 Becker et al, 59 as well as Pitz et al 57 and Baumert et al 78 reported on pONSM exclusively/separately. Turbin et al 43 provided the longest follow-up, reporting on 18 pONSM of a total of 64 ONSM patients, without specifying the details on the outcome for pONSM.…”

Section: Treatmentmentioning

confidence: 98%

“…4,13,14,28,41,53,54 These data, coupled with those showing the effectiveness of RT slowly, but definitely, challenged surgery as the treatment of choice in primary ONSM. 37,42,[55][56][57][58][59][60] It is likely that this would remain largely confined to continuously progressing, large, uni-or bilateral tumors in nonfunctioning eyes so as to prevent major intracranial spread, preferably by en bloc excision.…”

Section: Treatmentmentioning

confidence: 99%

“…The follow-up in these studies ranged from 1-7 years (mean, 3 years; median, 2 years), 58 and 1-6 years (median, 35.5 months). 59 This is likely adequate follow-up for the detection of RT-induced toxicity on optic pathways. The recent study of Baumert et al 78 reported on 22 patients with pONSM treated with SFRT in 4 European institutions.…”

Section: Treatmentmentioning

confidence: 99%

See 4 more Smart Citations

Primary optic nerve sheath meningioma

Jeremić

Pitz

2007

Cancer

Self Cite

View full text Add to dashboard Cite

Biotechnological production of weak organic acids such as succinic acid is most economically advantageous when carried out at low pH. Among naturally occurring microorganisms, several bacterial strains are known to produce considerable amounts of succinic acid under anaerobic conditions but they are inefficient in performing the low‐pH fermentation due to their physiological properties. We have proposed therefore a new strategy for construction of an aerobic eukaryotic producer on the basis of the yeast Yarrowia lipolytica with a deletion in the gene coding one of succinate dehydrogenase subunits. Firstly, an original in vitro mutagenesis‐based approach was proposed to construct strains with Ts mutations in the Y. lipolytica SDH1 gene. These mutants were used to optimize the composition of the media for selection of transformants with the deletion in the Y. lipolytica SDH2 gene. Surprisingly, the defects of each succinate dehydrogenase subunit prevented the growth on glucose but the mutant strains grew on glycerol and produced succinate in the presence of the buffering agent CaCO3. Subsequent selection of the strain with deleted SDH2 gene for increased viability allowed us to obtain a strain capable of accumulating succinate at the level of more than 45 g L−1 in shaking flasks with buffering and more than 17 g L−1 without buffering. The possible effect of the mutations on the utilization of different substrates and perspectives of constructing an industrial producer is discussed. Biotechnol. Bioeng. 2010;107:673–682. © 2010 Wiley Periodicals, Inc.

show abstract

Section: Treatmentmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 98%

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Primary optic nerve sheath meningioma

Jeremić

Pitz

2007

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Optic Nerve Sheath Meningiomas in Patients With Neurofibromatosis Type 2

Bosch

Wichmann²,

Boltshauser³

et al. 2006

Arch Ophthalmol

View full text Add to dashboard Cite

The role of radiation therapy and systemic treatments in meningioma: The present and the future

et al. 2023

View full text Add to dashboard Cite

Meningiomas are the most prevalent tumors of the central nervous system. Their standard treatment is surgery, which can be curative. Adjuvant radiotherapy treatment is reserved for newly diagnosed cases of grade II and grade III meningiomas in cases of recurrent disease or when surgery is not radical or feasible. However, around 20% of these patients cannot undergo further surgical and/or radiotherapy treatment. Systemic oncological therapy can find its place in this setting. Several tyrosine kinase inhibitors have been tested (gefitinib, erlotinib, sunitinib) with unsatisfactory or negative results. Bevacizumab has shown encouraging results in these settings of patients. Immunotherapy with immune checkpoint inhibitors has reported interesting results with modest objective response rates. Several ongoing studies are assessing different target therapies and multimodal therapies; the results are to be disclosed. Not only a better understanding of the molecular characteristics in meningiomas has allowed the gathering of more information regarding pathogenesis and prognosis, but in addition, the availability of new target therapy, immunotherapy, and biological drugs has widened the scope of potentially effective treatments in this patient population. The aim of this review was to explore the radiotherapy and systemic treatments of meningioma with an analysis of ongoing trials and future therapeutic perspectives.

show abstract

Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma

Cited by 109 publications

References 54 publications

Primary optic nerve sheath meningioma

Primary optic nerve sheath meningioma

Optic Nerve Sheath Meningiomas in Patients With Neurofibromatosis Type 2

The role of radiation therapy and systemic treatments in meningioma: The present and the future

Contact Info

Product

Resources

About